Charmquark TWEE Holds 6.28% Stake in ImmunoPrecise Antibodies

TL;DR

**Charmquark TWEE owns 6.28% of ImmunoPrecise Antibodies, a significant passive stake.**

AI Summary

Charmquark TWEE, a Belgian entity, filed an amended Schedule 13G/A on January 10, 2024, disclosing its beneficial ownership in ImmunoPrecise Antibodies Ltd. As of December 31, 2022, Charmquark TWEE beneficially owned 1,565,865 common shares, representing 6.28% of the company's outstanding shares. This filing indicates a significant passive investment by Charmquark TWEE, which could signal confidence in the company's long-term prospects to investors.

Why It Matters

This filing reveals a substantial institutional investor's position, which can influence market perception and potentially provide a floor for the stock price due to their large holding.

Risk Assessment

Risk Level: low — This filing indicates a passive investment, not an activist one, suggesting no immediate disruptive changes are expected from this shareholder.

Analyst Insight

Investors should note this significant institutional holding as a potential indicator of long-term value, but also recognize it's a passive stake, so no immediate strategic changes are implied.

Key Numbers

• 1,565,865 — Common Shares (beneficially owned by Charmquark TWEE)
• 6.28% — Percent of Class (represented by Charmquark TWEE's ownership)
• December 31, 2022 — Date of Event (when the ownership percentage was determined)
• January 10, 2024 — Filing Date (when the SC 13G/A amendment was filed)

Key Players & Entities

• Charmquark TWEE (company) — reporting person and beneficial owner
• ImmunoPrecise Antibodies Ltd. (company) — subject company (issuer)
• Belgium (company) — place of organization for Charmquark TWEE
• 03 Life Sciences (company) — organization name associated with ImmunoPrecise Antibodies Ltd.

Forward-Looking Statements

• Charmquark TWEE will maintain its passive investment in ImmunoPrecise Antibodies Ltd. for the foreseeable future. (Charmquark TWEE) — medium confidence, target: December 31, 2024

FAQ

Filing Documents

• sc13ga.htm (SC 13G/A) — 46KB
• 0000912282-24-000024.txt ( ) — 47KB

(a). Name of Issuer

Item 1 (a). Name of Issuer: Immunoprecise Antibodies Ltd.

(b). Address of Issuer's Principal Executive Offices

Item 1 (b). Address of Issuer's Principal Executive Offices: 3204, 4464 Markham Street Victoria, British Columbia V8Z 7X8 Canada

(a). Name of Person Filing

Item 2 (a). Name of Person Filing: i) Charmquark TWEE ii) Charmquark EEN

(b). Address of Principal Business Office or, if None, Residence

Item 2 (b). Address of Principal Business Office or, if None, Residence: Fabriekssfraat 7 Hamont-Achel Belgium 3930

(c). Citizenship

Item 2 (c). Citizenship: Belgium

(d). Title of Class of Securities

Item 2 (d). Title of Class of Securities: Common Shares, no par value

(e). CUSIP Number

Item 2 (e). CUSIP Number: 45257F200 Item 3. If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a: (a) Broker or dealer registered under Section 15 of the Act; (b) Bank as defined in Section 3(a)(6) of the Act; (c) Insurance Company as defined in Section 3(a)(19) of the Act; (d) Investment Company registered under Section 8 of the Investment Company Act; (e) Investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E); (f) Employee benefit plan or endowment plan in accordance with Rule 13d-1(b)(1)(ii)(F); (g) Parent holding company or control person, in accordance with Rule 13d-1(b)(1)(ii)(G); (h) A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act; (i) A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940: (j) Group, in accordance with Rule 13d-1(b)(1)(ii)(j). X If this statement is filed pursuant to Rule 13d-1(c), check this box. Item 4. Provide the following information regarding the aggregate number and percentage of the class of securities identified in Item 1. (a) Amount beneficially owned: 3,131,730 (b) Percent of class: 12.56%* *Based on 24,935,448 issued and outstanding shares of the Issuer as of November 10, 2022. (c) Number of shares as to which such person has: (i) Sole power to vote or to direct the vote: 0 (ii) Shared power to vote or to direct the vote: 3,131,730 (iii) Sole power to dispose or to direct the disposition of: 0 (iv) Shared power to dispose or to direct the disposition of: 3,131,730 Instruction. For computations regarding securities which represent a right to acquire an underlying security, see Rule 13d-3(d)(1). Item 5. If the statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the benef

Certification

Item 10. Certification. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. December 24_, 2023 (Date) By: /s/ Dirk Van Hyfte Dirk Van Hyfte, Director December 24, 2023 (Date) By: /s/ Ingrid Brands Ingrid Brands, Director

View Full Filing

View this SC 13G/A filing on SEC EDGAR